The Patent Finder

Maintenance fees coming due

Iovance Biotherapeutics, Inc.

19 maintenance fees come due in the 12 months from Nov 20, 2026, the next on Jan 30, 2027. Unpaid by Jul 30, 2027, that one lapses early.
A maintenance fee does not end a patent on its due date. It falls due at 3.5, 7.5 and 11.5 years from grant, and the patent lapses only if the fee is still unpaid at the end of the six month grace period that follows.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusFee dueLapses if unpaidExpiresConfidence
US 10,363,273Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same in Immunotherapy
In force
Fee due Jan 30, 2027
Lapses if unpaid Jul 30, 2027
 · Low confidence
Iovance Biotherapeutics, Inc.In forceJan 30, 2027Jul 30, 2027Low confidence
US 11,713,446Processes for Generating Til Products Enriched for Tumor Antigen-Specific T-Cells
In force
Fee due Feb 1, 2027
Lapses if unpaid Aug 2, 2027
 · High confidence
Iovance Biotherapeutics, Inc.In forceFeb 1, 2027Aug 2, 2027High confidence
US 10,398,734Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same in Immunotherapy
In force
Fee due Mar 3, 2027
Lapses if unpaid Sep 3, 2027
 · High confidence
Iovance Biotherapeutics, Inc.In forceMar 3, 2027Sep 3, 2027High confidence
US 10,415,015Engineered Artificial Antigen Presenting Cells for Tumor Infiltrating Lymphocyte Expansion
In force
Fee due Mar 17, 2027
Lapses if unpaid Sep 17, 2027
 · High confidence
Iovance Biotherapeutics, Inc.In forceMar 17, 2027Sep 17, 2027High confidence
US 10,420,799Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same in Immunotherapy
In force
Fee due Mar 24, 2027
Lapses if unpaid Sep 24, 2027
 · Low confidence
Iovance Biotherapeutics, Inc.In forceMar 24, 2027Sep 24, 2027Low confidence
US 10,463,697Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same in Immunotherapy
In force
Fee due May 5, 2027
Lapses if unpaid Nov 5, 2027
 · High confidence
Iovance Biotherapeutics, Inc.In forceMay 5, 2027Nov 5, 2027High confidence
US 11,819,517Methods of Using Tumor Infiltrating Lymphocytes in Double-Refractory Melanoma
In force
Fee due May 21, 2027
Lapses if unpaid Nov 22, 2027
 · Medium confidence
Iovance Biotherapeutics, Inc.In forceMay 21, 2027Nov 22, 2027Medium confidence
US 10,517,894Restimulation of Cryopreserved Tumor Infiltrating Lymphocytes
In force
Fee due Jun 30, 2027
Lapses if unpaid Jan 3, 2028
 · Low confidence
Iovance Biotherapeutics, Inc.In forceJun 30, 2027Jan 3, 2028Low confidence
US 11,857,573Restimulation of Cryopreserved Tumor Infiltrating Lymphocytes
In force
Fee due Jul 2, 2027
Lapses if unpaid Jan 3, 2028
 · Medium confidence
Iovance Biotherapeutics, Inc.In forceJul 2, 2027Jan 3, 2028Medium confidence
US 11,865,140Restimulation of Cryopreserved Tumor Infiltrating Lymphocytes
In force
Fee due Jul 9, 2027
Lapses if unpaid Jan 10, 2028
 · Medium confidence
Iovance Biotherapeutics, Inc.In forceJul 9, 2027Jan 10, 2028Medium confidence
9 more maintenance fees coming due in the 12 months from Nov 20, 2026 · Pro
10 of 19 patents shown. Soonest fee due date first, then patent number.
Pro members see every patent with a maintenance fee coming due: number, title, status, the due date, and the date it lapses if the fee goes unpaid through the grace period.
Upgrade to Pro
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited